71 related articles for article (PubMed ID: 23354849)
1. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
[TBL] [Abstract][Full Text] [Related]
2. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Ramalingam SS; Belani CP; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Gandara DR
J Thorac Oncol; 2010 Aug; 5(8):1279-84. PubMed ID: 20559150
[TBL] [Abstract][Full Text] [Related]
4. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Campbell NP; Kunnavakkam R; Leighl N; Vincent MD; Gandara DR; Koczywas M; Gitlitz BJ; Agamah E; Thomas SP; Stadler WM; Vokes EE; Kindler HL
Lung Cancer; 2012 Oct; 78(1):76-80. PubMed ID: 22831987
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ
J Clin Oncol; 2015 May; 33(13):1430-7. PubMed ID: 25452452
[TBL] [Abstract][Full Text] [Related]
6. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Ursprung S; Mossop H; Gallagher FA; Sala E; Skells R; Sipple JAN; Mitchell TJ; Chhabra A; Fife K; Matakidou A; Young G; Walker A; Thomas MG; Ortuzar MC; Sullivan M; Protheroe A; Oades G; Venugopal B; Warren AY; Stone J; Eisen T; Wason J; Welsh SJ; Stewart GD
BMC Cancer; 2021 Nov; 21(1):1238. PubMed ID: 34794412
[TBL] [Abstract][Full Text] [Related]
7. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Stenehjem DD; Toole M; Merriman J; Parikh K; Daignault S; Scarlett S; Esper P; Skinner K; Udager A; Tantravahi SK; Gill D; Straubhar AM; Agarwal AM; Grossmann KF; Samlowski WE; Redman B; Agarwal N; Alva A
Cancer Immunol Immunother; 2016 Aug; 65(8):941-9. PubMed ID: 27277816
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: A systematic review and meta-analysis.
Chen J; Ren JJ; Cai J; Wang X
Medicine (Baltimore); 2021 Aug; 100(31):e26788. PubMed ID: 34397830
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
12. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
13. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
[No Abstract] [Full Text] [Related]
14. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Escudier B; Porta C; Bono P; Powles T; Eisen T; Sternberg CN; Gschwend JE; De Giorgi U; Parikh O; Hawkins R; Sevin E; Négrier S; Khan S; Diaz J; Redhu S; Mehmud F; Cella D
J Clin Oncol; 2014 May; 32(14):1412-8. PubMed ID: 24687826
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
[TBL] [Abstract][Full Text] [Related]
16. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Monk P; Liu G; Stadler WM; Geyer S; Huang Y; Wright J; Villalona-Calero M; Wade J; Szmulewitz R; Gupta S; Mortazavi A; Dreicer R; Pili R; Dawson N; George S; Garcia JA
Invest New Drugs; 2018 Oct; 36(5):919-926. PubMed ID: 30083962
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.
Apolo AB; Karzai FH; Trepel JB; Alarcon S; Lee S; Lee MJ; Tomita Y; Cao L; Yu Y; Merino MJ; Madan RA; Parnes HL; Steinberg SM; Rodriguez BW; Seon BK; Gulley JL; Arlen PM; Dawson NA; Figg WD; Dahut WL
Clin Genitourin Cancer; 2017 Feb; 15(1):77-85. PubMed ID: 27328856
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
Pal S; Azad A; Bhatia S; Drabkin H; Costello B; Sarantopoulos J; Kanesvaran R; Lauer R; Starodub A; Hauke R; Sweeney CJ; Hahn NM; Sonpavde G; Richey S; Breen T; Kremmidiotis G; Leske A; Doolin E; Bibby DC; Simpson J; Iglesias J; Hutson T
Clin Cancer Res; 2015 Aug; 21(15):3420-7. PubMed ID: 25788492
[TBL] [Abstract][Full Text] [Related]
20. Hypertension in cancer patients treated with anti-angiogenic based regimens.
Wasserstrum Y; Kornowski R; Raanani P; Leader A; Pasvolsky O; Iakobishvili Z
Cardiooncology; 2015 Dec; 1(1):6. PubMed ID: 33530150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]